Sotera Health

SHC

Market cap $4.49B

Sotera Health Company (SHC) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Sotera Health Company (SHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Valvoline was Broyhill's largest contributor in the quarter, as the underlying unit economics are intact, while unit growth, service mix, and price continue moving in the same direction. Honeywell management accelerated the aerospace spin-off to the end of June, leaving behind a pure-play automation business that Broyhill believes is worth meaningfully more than the whole. Large pharma is structurally reliant on IQVIA's clinical trial architecture and proprietary data assets, and Broyhill thinks it is highly unlikely that AI can automate away the FDA approval process.

CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 31,838,253 shares of its common stock, par value $0.01 per share. All 31,838,253 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders.

Sotera Health Company (SHC) Q1 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Sotera Health (SHC) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Sotera Health Company (SHC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.14 per share a year ago.

Q1 2026 net revenues increased 10.0%, or 6.5% on a co nstant currenc y basis, compared to Q1 2025 Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025 Q1 2026 Adjusted EBITDA ( 1 ) increased 10.5%, or 6.9% on a constant currency basis Q1 2026 Adjusted EPS (1) of $0.18 , an increase of 29% per diluted share Company reaffirms full-year 2026 outlook of 5.0% - 6.5% net revenues growth and 5.5% - 7.0% Adjusted EBITDA growth, both on a constant currency basis Company announced planned CEO transition in a separate release today CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three months ended March 31, 2026. “We delivered a strong start to the year, with solid revenue and Adjusted EBITDA growth while driving margin expansion,” said Chairman and Chief Executive Officer, Michael B.

Alton Shader, CEO of Viant Medical®, to become CEO and join the Board of Directors, effective May 26, 2026 Chairman and CEO Michael B. Petras, Jr. will serve as Executive Chairman of the Board of Directors CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced the appointment of Alton Shader to the role of Chief Executive Officer (“CEO”) of the Company, effective May 26, 2026, as part of a planned leadership transition.

CLEVELAND, April 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2026 before the market opens on Tuesday, May 5, 2026. Following the release, management will host a conference call at 9:00 a.m.